Share This

Hot News

中國制新冠特效藥將上市 @ 2021-12-11T12: Back Hot News
Keyword:新冠
Concept:首款國產特效藥獲批 , 中國首個新冠病毒中和抗體聯合
大陸國家藥品監督管理局8日晚間發布消息,宣布應急批准騰盛華創醫藥技術(北京)有限公司新冠病毒中和抗體聯合治療藥物安巴韋單抗注射液(BRII-196)及羅米司韋單抗注射液(BRII-198)注冊申請。這是大陸首家獲批的自主知識產權新冠病毒中和抗體聯合治療藥物。
12月8日,國家感染性疾病臨床醫學中心、深圳市第三人民醫院與清華大學、騰盛博藥合作研發的新冠單克隆中和抗體“安巴韋單抗/羅米司韋單抗”聯合療法(此前稱BRII-196/BRII-198聯合療法)獲中國藥品監督管理局上市批准。該特效藥上市後,將用於治療輕型和普通型且伴有進展為重型(包括住院或死亡)高風險因素的成人和青少年(12-17歲)新型冠狀病毒感染患者。其中青少年(12-17歲)適應症人群為附條件批准。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.